March 2016

The superhero Iron Man inspired a three-year-old hemophilia patient to continue his treatment at the Children's Hospital of Philadelphia (CHOP), where he had been a patient nearly all his life, and adopt the nickname "Iron Max."

Researchers from the LFB USA Inc. in Framingham, Mass. engineered rabbits and raised them in order to produce milk with the blood clotting factor VII (FVII) agent for use in human patients with hemophilia.

The use of twice-weekly prophylactic regimens to treat hemophilia A was shown to be successful among patients treated with BAX 855.

Late last year, the US Food and Drug Administration (FDA) granted the bispecific antibody “ACE910†from Chugai Pharmaceutical Co, Ltd with a Breakthrough Therapy Designation as a treatment for hemophilia A.

All von Willebrand Disease patients successfully managed bleeding episode using BAX 111 treatment, according to a study conducted by Baxalta. The study was published in the journal Blood.

Researchers report the clotting factor deficiency causing hemophilia A may be reversed using pluripotent stem cells (iPSCs).